Severe Aplastic Anaemia Working Party (SAAWP)
Study type:
Study number:
8409077
Type of transplant / Cell therapy:
Allogeneic
Diseases:
Bone marrow failure
Short title:
ATG in aPRCA
Primary objective:
To investigate the effectivity of treatment with ATG in patients with acquired PRCA.
Key inclusion criteria:
Patients are eligible if:
1) they have been diagnosed with acquired PRCA and
2) received ATG treatment between 2000 and 2018.
1) they have been diagnosed with acquired PRCA and
2) received ATG treatment between 2000 and 2018.
Country:
All EBMT member countries
Principal investigator:
Stijn Halkes
EBMT Study coordinator:
Brian Piepenbroek
Study coordinator email:
saawp@ebmt.org
EBMT Study Unit:
Leiden Study Unit
Reason for processing personal data:
Research and Development of new and improved transplant, cell therapy and immunosuppression procedures.
Categories of personal data collected:
Medical data already reported to the EBMT Registry
Study Specific Questionnaire (MED-C)
Recipients who may access the data:
Leiden Study Unit
Statistical Unit
Investigators
3rd-party processors of Personal Data on behalf of EBMT/Service provider:
Non
Privacy notices
Article 6 lawful basis for processing personal data:
Article 6.1 (a) - Consent (Collection)
Article 9 basis for processing special category data:
Article 9(2) (a) - Consent (Collection)
Data Protection Impact Assessments
Rights available to individuals:
Access
Data portability
Rectification
Objection
Deletion
Is a Data Protection Impact Assessment required?:
DPIA performed for EBMT Registry (WP & NIS Studies)
Retention Schedule (if possible):
at least 5 years after the final report or first publication of study results